A clinical study showed that, consistent with TAAR1 agonist suppression of REM sleep in animal studies, the TAAR1 agonist ulotaront reduced daytime sleep onset REM periods and nighttime REM duration in patients with narcolepsy-cataplexy (21). Here, TAAR1 is linked to narcolepsy-cataplexy syndrome.